Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer
Anand, Aseem ; Minarik, David LU ; Kaboteh, Reza ; Lindgren Belal, Sarah LU
; Reza Felix, Mariana
LU
; Josefsson, Andreas
; Edenbrandt, Lars
and Bjartell, Anders
LU
(2015)
American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium
In Journal of Clinical Oncology
33(15 Suppl).
p.5044-5044
- Abstract
- Background: A consistent imaging biomarker to standardize the evaluation of change in bone scan is an unmet need for patients (pts) with bone metastasis. BSI is quantitative interpretation of bone scan in pts with metastatic prostate cancer (mPCa). Here we have performed analytical and clinical studies to evaluate the change in computer automated BSI as a consistent imaging biomarker in pts with mPCa.
Methods: Analytical studies with bone scan simulation using XCAT phantoms and SIMIND-MC program were performed to evaluate the consistency of automated BSI. Specifically, to assess linearity and accuracy, bone scan of 50 phantoms were simulated with tumor burden ranging from low to high disease confluence – from 0.10 to... (More) - Background: A consistent imaging biomarker to standardize the evaluation of change in bone scan is an unmet need for patients (pts) with bone metastasis. BSI is quantitative interpretation of bone scan in pts with metastatic prostate cancer (mPCa). Here we have performed analytical and clinical studies to evaluate the change in computer automated BSI as a consistent imaging biomarker in pts with mPCa.
Methods: Analytical studies with bone scan simulation using XCAT phantoms and SIMIND-MC program were performed to evaluate the consistency of automated BSI. Specifically, to assess linearity and accuracy, bone scan of 50 phantoms were simulated with tumor burden ranging from low to high disease confluence – from 0.10 to 13.0 BSI. To assess precision, another set of 50 phantoms were divided into 5 subgroups, each containing simulated bone scans of 10 phantoms at 0.5, 1.0, 3.0, 5.0 and 10.0 BSI, respectively. Additionally, to evaluate the clinical utility of automated BSI, two follow-up bone scans of 145 pts with progressing mPCa, irrespective of therapy regiment, were analyzed for change in BSI. The primary objective was to evaluate the association of change in BSI against overall survival (OS). The computer automated BSI was calculated using the software EXINI boneBSI. Cox regression and Kaplan Meier analysis were used to evaluate association between BSI and OS.
Results: Pearson correlation to evaluate linearity and accuracy of BSI, in the given range from 0.10 to 13.0, was observed to be 0.995 (N=50, 95% CI 0.99–0.99, p<0.0001). The mean coefficient of variation indicating precision of BSI at each of the pre-defined tumor burden was observed to be less than 20%. Change in BSI of 145 pts was significantly associated with OS (HR 1.1, p<0.0001). The median OS for 110 (66%) pts who had a rise in BSI ( >0.10) was 31 weeks, 35 (34%) pts who had a decline or no change in BSI reached a median 72 weeks (HR 1.9, p 0.0002).
Conclusions: Computer automated BSI is a consistent biomarker which can standardize the quantitative analysis of change in bone metastasis of pts with mPCa. The clinical utility of automated BSI, in multivariate biomarker panel, will be validated in subsequent studies. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/124978cd-f3c6-4788-a4cf-383f36b1344a
- author
- Anand, Aseem
; Minarik, David
LU
; Kaboteh, Reza
; Lindgren Belal, Sarah
LU
; Reza Felix, Mariana
LU
; Josefsson, Andreas
; Edenbrandt, Lars
and Bjartell, Anders
LU
- publishing date
- 2015-05-20
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Oncology
- volume
- 33
- issue
- 15 Suppl
- pages
- 5044 - 5044
- publisher
- American Society of Clinical Oncology
- conference name
- American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium
- conference location
- Orlando, United States
- conference dates
- 2015-02-26 - 2015-02-28
- ISSN
- 0732-183X
- DOI
- 10.1200/jco.2015.33.15_suppl.5044
- language
- English
- LU publication?
- no
- id
- 124978cd-f3c6-4788-a4cf-383f36b1344a
- date added to LUP
- 2022-12-13 21:44:37
- date last changed
- 2022-12-14 08:30:11
@misc{124978cd-f3c6-4788-a4cf-383f36b1344a,
abstract = {{<b>Background:</b> A consistent imaging biomarker to standardize the evaluation of change in bone scan is an unmet need for patients (pts) with bone metastasis. BSI is quantitative interpretation of bone scan in pts with metastatic prostate cancer (mPCa). Here we have performed analytical and clinical studies to evaluate the change in computer automated BSI as a consistent imaging biomarker in pts with mPCa.<br/><br/><b>Methods:</b> Analytical studies with bone scan simulation using XCAT phantoms and SIMIND-MC program were performed to evaluate the consistency of automated BSI. Specifically, to assess linearity and accuracy, bone scan of 50 phantoms were simulated with tumor burden ranging from low to high disease confluence – from 0.10 to 13.0 BSI. To assess precision, another set of 50 phantoms were divided into 5 subgroups, each containing simulated bone scans of 10 phantoms at 0.5, 1.0, 3.0, 5.0 and 10.0 BSI, respectively. Additionally, to evaluate the clinical utility of automated BSI, two follow-up bone scans of 145 pts with progressing mPCa, irrespective of therapy regiment, were analyzed for change in BSI. The primary objective was to evaluate the association of change in BSI against overall survival (OS). The computer automated BSI was calculated using the software EXINI boneBSI. Cox regression and Kaplan Meier analysis were used to evaluate association between BSI and OS.<br/><br/><b>Results:</b> Pearson correlation to evaluate linearity and accuracy of BSI, in the given range from 0.10 to 13.0, was observed to be 0.995 (N=50, 95% CI 0.99–0.99, p<0.0001). The mean coefficient of variation indicating precision of BSI at each of the pre-defined tumor burden was observed to be less than 20%. Change in BSI of 145 pts was significantly associated with OS (HR 1.1, p<0.0001). The median OS for 110 (66%) pts who had a rise in BSI ( >0.10) was 31 weeks, 35 (34%) pts who had a decline or no change in BSI reached a median 72 weeks (HR 1.9, p 0.0002).<br/><br/><b>Conclusions:</b> Computer automated BSI is a consistent biomarker which can standardize the quantitative analysis of change in bone metastasis of pts with mPCa. The clinical utility of automated BSI, in multivariate biomarker panel, will be validated in subsequent studies.}},
author = {{Anand, Aseem and Minarik, David and Kaboteh, Reza and Lindgren Belal, Sarah and Reza Felix, Mariana and Josefsson, Andreas and Edenbrandt, Lars and Bjartell, Anders}},
issn = {{0732-183X}},
language = {{eng}},
month = {{05}},
note = {{Conference Abstract}},
number = {{15 Suppl}},
pages = {{5044--5044}},
publisher = {{American Society of Clinical Oncology}},
series = {{Journal of Clinical Oncology}},
title = {{Computer automated bone scan index (BSI) as an analytically validated imaging biomarker to quantitate change in bone scan of patients with metastatic prostate cancer}},
url = {{http://dx.doi.org/10.1200/jco.2015.33.15_suppl.5044}},
doi = {{10.1200/jco.2015.33.15_suppl.5044}},
volume = {{33}},
year = {{2015}},
}